GPCRのPER（株価収益率）は？

Structure Therapeutics Inc. American Depositary Shares（GPCR）は現在PER 103.45倍で取引されています。

GPCRのROE（自己資本利益率）は？

Structure Therapeutics Inc. American Depositary SharesのROEは-11.79%です。

GPCRの配当利回りは？

Structure Therapeutics Inc. American Depositary Sharesの配当利回りは0.00%です。

GPCRの品質スコア（Quality Score）は？

当社のAIはGPCRの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

GPCRは今が買い時ですか？

当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

GPCRはどのセクターに属しますか？

Structure Therapeutics Inc. American Depositary SharesはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

GPCR (NASDAQ) 株価分析 | STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

GPCR AI Analysis Summary

Our AI summary for GPCR: Structure Therapeutics Inc. American Depositary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 103.45, ROE of -11.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GPCR

Structure Therapeutics Inc. American Depositary Shares

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 48.36

0.32 (0.67%) Day Change

Watchlist Portfolio Compare Chart

103.45

P/E

0.00

D/E

-11.8%

ROE

-11.3%

ROA

0.00%

Div Yield

4.32

PEG

STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 48.36 Price 0.32 (0.67%) Day Change	NEWS SCORE: 99

GPCR, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	48.36
PBV / Sector	2.36 / 44,219.29
Earning Per Share	-2.42

PE / Sector	103.45 / 19.28
PEG or PE/Growth / Sector	4.32 / 1.23
Average 1M Daily Value	26.75 M GREAT
Average 1W Daily Value	19.13 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-11.31 / 185,260.96
ROA Average (%) / Sector	-20.97 / 36,684.70
ROA Change Average (%) / Sector	-24.75 / 422,221.66
ROE (%) / Sector	-11.79 / 243,762.23
ROE Average (%) / Sector	-2.10 / 48,758.47
ROE Change Average (%) / Sector	-45.12 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

登録情報

Analyze Date	2026-08-04 08:01:36
Symbol	GPCR
Name	STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	71.07 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3,414.42 / 9,645.64

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Phone: 650 457 1978

Website: https://structuretx.com

Employees: 233

Sector: Healthcare >> Biotechnology

Description: Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.